169 related articles for article (PubMed ID: 11116063)
1. HIV protease inhibitors stimulate hepatic triglyceride synthesis.
Lenhard JM; Croom DK; Weiel JE; Winegar DA
Arterioscler Thromb Vasc Biol; 2000 Dec; 20(12):2625-9. PubMed ID: 11116063
[TBL] [Abstract][Full Text] [Related]
2. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro.
Lenhard JM; Furfine ES; Jain RG; Ittoop O; Orband-Miller LA; Blanchard SG; Paulik MA; Weiel JE
Antiviral Res; 2000 Aug; 47(2):121-9. PubMed ID: 10996400
[TBL] [Abstract][Full Text] [Related]
3. Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice.
Xu A; Yin S; Wong L; Chan KW; Lam KS
Endocrinology; 2004 Feb; 145(2):487-94. PubMed ID: 14592951
[TBL] [Abstract][Full Text] [Related]
4. Dietary fat alters HIV protease inhibitor-induced metabolic changes in mice.
Lenhard JM; Croom DK; Weiel JE; Spaltenstein A; Reynolds DJ; Furfine ES
J Nutr; 2000 Sep; 130(9):2361-6. PubMed ID: 10958836
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells.
Schütt M; Zhou J; Meier M; Klein HH
J Endocrinol; 2004 Dec; 183(3):445-54. PubMed ID: 15590971
[TBL] [Abstract][Full Text] [Related]
6. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.
Périard D; Telenti A; Sudre P; Cheseaux JJ; Halfon P; Reymond MJ; Marcovina SM; Glauser MP; Nicod P; Darioli R; Mooser V
Circulation; 1999 Aug; 100(7):700-5. PubMed ID: 10449690
[TBL] [Abstract][Full Text] [Related]
7. The HIV protease inhibitor ritonavir increases lipoprotein production and has no effect on lipoprotein clearance in mice.
Riddle TM; Schildmeyer NM; Phan C; Fichtenbaum CJ; Hui DY
J Lipid Res; 2002 Sep; 43(9):1458-63. PubMed ID: 12235177
[TBL] [Abstract][Full Text] [Related]
8. In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.
Shibata N; Gao W; Okamoto H; Kishida T; Yoshikawa Y; Takada K
J Pharm Pharmacol; 2002 Feb; 54(2):221-9. PubMed ID: 11848286
[TBL] [Abstract][Full Text] [Related]
9. Hyperlipidemia under treatment with proteinase inhibitors.
Segerer S; Bogner JR; Walli R; Loch O; Goebel FD
Infection; 1999; 27(2):77-81. PubMed ID: 10219634
[TBL] [Abstract][Full Text] [Related]
10. HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications.
Kaul DR; Cinti SK; Carver PL; Kazanjian PH
Pharmacotherapy; 1999 Mar; 19(3):281-98. PubMed ID: 10221367
[TBL] [Abstract][Full Text] [Related]
11. Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation.
Vernochet C; Azoulay S; Duval D; Guedj R; Ailhaud G; Dani C
AIDS; 2003 Oct; 17(15):2177-80. PubMed ID: 14523274
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 protease inhibitors. A review for clinicians.
Deeks SG; Smith M; Holodniy M; Kahn JO
JAMA; 1997 Jan; 277(2):145-53. PubMed ID: 8990341
[TBL] [Abstract][Full Text] [Related]
13. Alterations in the Notch4 pathway in cerebral endothelial cells by the HIV aspartyl protease inhibitor, nelfinavir.
Grigorian A; Hurford R; Chao Y; Patrick C; Langford TD
BMC Neurosci; 2008 Feb; 9():27. PubMed ID: 18302767
[TBL] [Abstract][Full Text] [Related]
14. Stimulation of vitamin A(1) acid signaling by the HIV protease inhibitor indinavir.
Lenhard JM; Weiel JE; Paulik MA; Furfine ES
Biochem Pharmacol; 2000 May; 59(9):1063-8. PubMed ID: 10704935
[TBL] [Abstract][Full Text] [Related]
15. Select HIV protease inhibitors alter bone and fat metabolism ex vivo.
Jain RG; Lenhard JM
J Biol Chem; 2002 May; 277(22):19247-50. PubMed ID: 11937496
[TBL] [Abstract][Full Text] [Related]
16. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
Granfors MT; Wang JS; Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):79-85. PubMed ID: 16433896
[TBL] [Abstract][Full Text] [Related]
17. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.
Young J; Weber R; Rickenbach M; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
Antivir Ther; 2005; 10(5):585-91. PubMed ID: 16152752
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with accelerated atherosclerosis in HIV-1-infected persons treated with protease inhibitors.
Lai S; Lai H; Celentano DD; Vlahov D; Ren S; Margolick J; Lima JA; Bartlett JG
AIDS Patient Care STDS; 2003 May; 17(5):211-9. PubMed ID: 12816615
[TBL] [Abstract][Full Text] [Related]
19. Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system.
Zhang L; Gorset W; Washington CB; Blaschke TF; Kroetz DL; Giacomini KM
Drug Metab Dispos; 2000 Mar; 28(3):329-34. PubMed ID: 10681378
[TBL] [Abstract][Full Text] [Related]
20. Human immunodeficiency virus protease inhibitors interact with ATP binding cassette transporter 4/multidrug resistance protein 4: a basis for unanticipated enhanced cytotoxicity.
Fukuda Y; Takenaka K; Sparreboom A; Cheepala SB; Wu CP; Ekins S; Ambudkar SV; Schuetz JD
Mol Pharmacol; 2013 Sep; 84(3):361-71. PubMed ID: 23775562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
